Antitumor activity of Juzen-Taiho-Toh (JTX) and combination effect of JTX with
antitumor agents were studied using murine
tumors. In order to determine the antitumor activity of JTX, mice inoculated ip with IMC
carcinoma (1 X 10(6) cells/CDF1 mouse),
sarcoma-180(1 X 10(6) cells/ICR mouse) or Meth-A
fibrosarcoma (1 X 10(6) cells/BALB/c mouse) were treated with JTX (12.5-50 mg/kg/day) ip on day 1 through day 10, and the survival days of mice were examined. Treatment with 25 mg/kg/day produced 38.7% increase of life span against IMC
carcinoma. However, no antitumor effect was observed on solid form of these
tumors by the daily treatment with JTX. Combination effect of JTX and
antitumor agents was also examined. ICR mice inoculated sc with 1 X 10(6) cells of sarcoma-180 on day 0 were treated with JTX (2,000 mg/kg/day) po on day-7 through day 30. In addition, some of these groups received
mitomycin C (5 mg/kg),
cytoxan (67 mg/kg) or
adriamycin (2.5 mg/kg) iv on days 3, 8 and 11, and the size of
tumor grown in sc site was measured by a caliper. In combination with JTX,
mitomycin C resulted in a significantly greater
tumor growth inhibition than could be obtained with
mitomycin C alone. Secondly, BALB/c or C57BL/6 mice inoculated sc with 1 X 10(4) cells of Meth-A
fibrosarcoma or 1 X 10(5) cells of
B16 melanoma on day 0 were treated with JTX (2,000 mg/kg/day) po on day 1 through day 30. Some of these group received ip with
mitomycin C (3 mg/kg),
adriamycin (2 mg/kg),
5-FU (33 mg/kg) or
cytoxan (67 mg/kg) on days 3, 6, 9, 12, 15 and 18. From this result, the group treated with JTX and
mitomycin C also showed a higher
tumor-growth inhibition. Thus, a combination of a high dose of
mitomycin C with JTX was more effective than
mitomycin C alone.